Vertex Pharmaceuticals (VRTX) Free Cash Flow Growth (1y) (2010 - 2026)
Vertex Pharmaceuticals (VRTX) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 137.65% |
| 10 | Revolution Medicines | 37.32 Bn | 37.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.37% |
| Dec 31, 2025 | -29.15% |
| Sep 30, 2025 | -12.48% |
| Jun 30, 2025 | 124.26% |
| Mar 31, 2025 | -37.15% |
| Dec 31, 2024 | 178.75% |
| Sep 30, 2024 | 6.05% |
| Jun 30, 2024 | -455.66% |
| Mar 31, 2024 | 44.35% |
| Dec 31, 2023 | -83.11% |
| Sep 30, 2023 | 36.23% |
| Jun 30, 2023 | -1.08% |
| Mar 31, 2023 | -3.90% |
| Dec 31, 2022 | 11.96% |
| Sep 30, 2022 | 3.03% |
| Jun 30, 2022 | 535.30% |
| Mar 31, 2022 | 5.00% |
| Dec 31, 2021 | 110.26% |
| Sep 30, 2021 | 19.35% |
| Jun 30, 2021 | -124.45% |